1 active not recruiting, 1 not yet recruiting, 1 suspended. 3 Phase 2, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Active not recruiting 1, Not yet recruiting 1, Suspended 1 |
| Phase 1 | 1 | Suspended 1 |
| Phase 3 | 1 | Not yet recruiting 1 |
Follow Teropavimab: new trials by email Literature Review of Teropavimab trials Research Report on Teropavimab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Twice Yearly Lenacapavir, Teropavimab, and Zinlirvimab in the Pediatric Population With HIV-1 Lenacapavir Tablet, Lenacapavir Injection, Teropavimab - HIV-1-infection | Phase 2 / Phase 3 | Not yet recruiting | Gilead Sciences | 25 | 2026-11-01 | 2026-11-19 |
| Evaluation of Safety, Immunogenicity and Efficacy of a Triple Immune Regimen in Adults Initiated on ART During Acute HIV-1 ChAdOx1.tHIVconsv1, ChAdOx1.HIVconsv62, MVA.tHIVconsv3 - HIV-1-infection | Phase 1 / Phase 2 | Suspended | National Institute of Allergy and Infectious Diseases (NIAID) | 36 | 2024-04-01 | 2026-09-02 |
| A Study of Teropavimab and Zinlirvimab in Combination With Capsid Inhibitor Lenacapavir in Virologically Suppressed Adults With HIV-1 Infection Teropavimab, Zinlirvimab, Lenacapavir Tablet - HIV-1 Infection | Phase 2 | Active not recruiting | Gilead Sciences | 83 | 2023-05-15 | 2026-04-27 |
Gilead Sciences (2) · National Institute of Allergy and Infectious Diseases (NIAID) (1)
United States (3) · Australia (1) · Brazil (1) · Canada (1) · Puerto Rico (1)